These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
42 results:

  • 1. Investigating druggable kinases for targeted therapy in retinoblastoma.
    Jeyaprakash K; Kumaran M; Kim U; Santhi R; Muthukkaruppan V; Devarajan B; Vanniarajan A
    J Hum Genet; 2024 Sep; 69(9):467-474. PubMed ID: 38956221
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.
    Zob DL; Augustin I; Caba L; Panzaru MC; Popa S; Popa AD; Florea L; Gorduza EV
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614156
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. LncRNA SNHG25 Promotes Glioma Progression Through Activating MAPK Signaling.
    Wu Z; Lun P; Ji T; Niu J; Sun X; Liu X; Xu J
    Mol Neurobiol; 2022 Nov; 59(11):6993-7005. PubMed ID: 36071306
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular alterations in retinoblastoma beyond RB1.
    Mendonça V; Evangelista AC; P Matta B; M Moreira MÂ; Faria P; Lucena E; Seuánez HN
    Exp Eye Res; 2021 Oct; 211():108753. PubMed ID: 34478740
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. An overview of binimetinib for the treatment of melanoma.
    Specenier P
    Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/mek2 inhibitor trametinib in patients with solid tumors.
    Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
    Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
    Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
    Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
    Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
    Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
    Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by map2k2 and B2M mutations in melanoma.
    Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
    Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
    Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
    Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.
    Ma XL; Shang F; Ni W; Zhu J; Luo B; Zhang YQ
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2351-2366. PubMed ID: 30225541
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Trametinib (GSK1120212).
    Zeiser R; Andrlová H; Meiss F
    Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Cobimetinib.
    Signorelli J; Shah Gandhi A
    Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
    Latimer NR; Bell H; Abrams KR; Amonkar MM; Casey M
    Cancer Med; 2016 May; 5(5):806-15. PubMed ID: 27172483
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Structure-Activity Relationship Study of the Neuritogenic Potential of the Glycan of Starfish Ganglioside LLG-3 (‡).
    Yamagishi M; Hosoda-Yabe R; Tamai H; Konishi M; Imamura A; Ishida H; Yabe T; Ando H; Kiso M
    Mar Drugs; 2015 Dec; 13(12):7250-74. PubMed ID: 26690179
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma.
    Fernandes JD; Hsieh R; de Freitas LA; Brandao MA; Lourenço SV; Sangueza M; Nico MM
    Am J Dermatopathol; 2015 Dec; 37(12):892-7. PubMed ID: 26588333
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. mek2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
    He H; Yao M; Zhang W; Tao B; Liu F; Li S; Dong Y; Zhang C; Meng Y; Li Y; Hu G; Luo C; Zong H; Lu Y
    Cell Mol Immunol; 2016 Sep; 13(5):658-68. PubMed ID: 26189368
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
    Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
    Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
    Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
    JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.